Inclisiran and the ORION clinical development programme Slide deck kindly donated as an educational resource by: Professor FJ Raal, University of the Witwatersrand, Johannesburg, …

These latest slide decks capture the essentials of the mechanism of inclisiran, and results from trials with this new therapeutic approach to inhibiting PCSK9. Accompanying videos provide …

Aug 4, 2015 · A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-PCSsc), Targeting PCSK9 for the Treatment of Hypercholesterolemia: Initial Phase 1 Study Results

Sep 10, 2025 · VICTORION-Difference: Inclisiran effective for LDL-C in high CV risk patients Inclisiran therapy brought more patients with hypercholesterolaemia at high or very high risk of …

Aug 28, 2024 · Study title/design: V-MONO: inclisiran monotherapy in primary hypercholesterolaemia (NCT05763875) Trial NCT05763875 (Completed) Aim To determine if …

Aug 30, 2023 · When added to statin therapy, twice-yearly* inclisiran consistently reduces low-density lipoprotein cholesterol (LDL-C) beyond six years, according to late-breaking data …

May 31, 2019 · Inclisiran (an siRNA therapeutic targeting PCSK9) showed promise in patients with homozygous familial hypercholesterolaemia (FH, inherited high cholesterol) in the proof-of …

Feb 22, 2018 · V-MONO Study title/design: V-MONO: inclisiran monotherapy in primary hypercholesterolaemia (NCT05763875) Trial NCT05763875 (Completed) Aim To determine if …

Dec 31, 2024 · Phase 3 study to evaluate the efficacy and safety of lerodalcibep (LIB003) with evolocumab in HoFH (NCT04034485) Study title/design Phase 3 study to evaluate the efficacy …

Complementing resources already available, PCSK9 Forum is pleased to announce the next in this series of educational slide decks which focus on a novel approach to PCSK9 inhibition. …